Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2019-04-02, Stock:JNJ, The news for the past five days is as follows:
2019-03-26: NEWS1: Bayer & JNJ Settle Numerous Xarelto Lawsuits for $775 Million.NEWS2: Bayer & JNJ Settle Numerous Xarelto Lawsuits for $775 Million.NEWS3: Amid talk of buyout, Peninsula biotech zeroes in on its blood-thinner antidote.NEWS4: Purdue Pharma agrees to $270 million settlement in Oklahoma opioid case.NEWS5: Purdue Pharma agrees to $270 mln settlement in Oklahoma opioid case.NEWS6: Bayer & JNJ Settle Numerous Xarelto Lawsuits for $775 Million.NEWS7: 5 Must-See Stock Charts: Oil, JNJ, BBBY, CCL, and NIO.NEWS8: Dow Jones Climbs As One Of Its Maligned Stocks Nears Buy Point.NEWS9: OxyContin Maker Purdue Pharma Agrees to $270 Million Settlement With Oklahoma.NEWS10: Health Care Sector Update for 03/26/2019: ALDX, ZOM, CANF, NNVC, JNJ, PFE, ABT, MRK, AMGN.NEWS11: Health Care Sector Update for 03/26/2019: ALDX, ZOM, CANF, NNVC, JNJ, PFE, ABT, MRK, AMGN.NEWS12: OxyContin maker Purdue agrees to settle Oklahoma opioid case - source.NEWS13: Johnson & Johnson (JNJ) Dips More Than Broader Markets: What You Should Know.NEWS14: Johnson & Johnson (JNJ) Dips More Than Broader Markets: What You Should Know.
2019-03-27: NEWS1: New Jersey jury finds J&J not liable in latest talc cancer trial.NEWS2: J&J settles three mesothelioma talc cases-plaintiffs' lawyer.NEWS3: New Jersey jury finds J&J not liable in latest talc cancer trial.NEWS4: 5 Cancer-Fighting Stocks to Boost Portfolio Gains.NEWS5: 5 Cancer-Fighting Stocks to Boost Portfolio Gains.NEWS6: Johnson & Johnson Vision Announces Availability of ACUVUE OASYS with TRANSITIONS LIGHT INTELLIGENT TECHNOLOGY in the U.S..NEWS7: 5 Cancer-Fighting Stocks to Boost Portfolio Gains.NEWS8: 6 Gene Therapy M&A Targets On The Radar.NEWS9: J&J Files sBLA for Darzalex in Expanded Myeloma Patient Group.NEWS10: J&J Files sBLA for Darzalex in Expanded Myeloma Patient Group.NEWS11: iShares Core S&P Total U.S. Stock Market ETF Experiences Big Inflow.NEWS12: iShares Core S&P Total U.S. Stock Market ETF Experiences Big Inflow.NEWS13: 3 Reasons Why Johnson & Johnson (JNJ) Is a Great Growth Stock.NEWS14: 3 Reasons Why Johnson & Johnson (JNJ) Is a Great Growth Stock.NEWS15: Axsome Adds To Strong Gains After FDA Grants Breakthrough Designation For Depression Drug.NEWS16: J&J Files sBLA for Darzalex in Expanded Myeloma Patient Group.NEWS17: Health Care Sector Update for 03/27/2019: AXSM, BLRX, WCG, CNC, JNJ, PFE, ABT, MRK, AMGN.NEWS18: Health Care Sector Update for 03/27/2019: AXSM, BLRX, WCG, CNC, JNJ, PFE, ABT, MRK, AMGN.NEWS19: 3 Reasons Why Johnson & Johnson (JNJ) Is a Great Growth Stock.NEWS20: 5 Must-See Stock Charts: Oil, JNJ, BBBY, CCL, and NIO.NEWS21: 5 Must-See Stock Charts: Oil, JNJ, BBBY, CCL, and NIO.
2019-03-28: NEWS1: New York sues billionaire family behind maker of OxyContin.NEWS2: New York sues billionaire family behind maker of OxyContin.NEWS3: AstraZeneca's Forxiga Gets Nod in Japan for Type I Diabetes.NEWS4: AstraZeneca's Forxiga Gets Nod in Japan for Type I Diabetes.NEWS5: More Mud on Johnson & Johnson?.NEWS6: The Zacks Analyst Blog Highlights: Roche, Celgene, Johnson and Johnson, Bayer and Sunesis Pharmaceuticals.NEWS7: The Zacks Analyst Blog Highlights: Roche, Celgene, Johnson and Johnson, Bayer and Sunesis Pharmaceuticals.NEWS8: Johnson & Johnson Vision Announces Availability of ACUVUE OASYS with TRANSITIONS LIGHT INTELLIGENT TECHNOLOGY in Canada.NEWS9: State's opioid suit hits billionaire family behind OxyContin.NEWS10: This is Why Johnson & Johnson (JNJ) is a Great Dividend Stock.NEWS11: This is Why Johnson & Johnson (JNJ) is a Great Dividend Stock.NEWS12: AstraZeneca's Forxiga Gets Nod in Japan for Type I Diabetes.NEWS13: NY opioid lawsuit hits billionaire family behind OxyContin.NEWS14: The Zacks Analyst Blog Highlights: Roche, Celgene, Johnson and Johnson, Bayer and Sunesis Pharmaceuticals.NEWS15: 3 Small Biotech Stocks Hitting New Highs.NEWS16: Health Care Sector Update for 03/28/2019: CTST, AMRN, VLRX, JNJ, PFE, ABT, MRK, AMGN.NEWS17: Health Care Sector Update for 03/28/2019: CTST, AMRN, VLRX, JNJ, PFE, ABT, MRK, AMGN.NEWS18: Johnson & Johnson prevails in New Jersey talc cancer trial.NEWS19: This is Why Johnson & Johnson (JNJ) is a Great Dividend Stock.NEWS20: PRESS DIGEST- New York Times business news - March 28.NEWS21: J&J&apos;s Sudden Talc-Cancer Settlements Aren&apos;t Its Usual Style.NEWS22: New York sues Purdue Pharma and Sackler family over opioid crisis.NEWS23: New Jersey jury finds J&J not liable in talc cancer trial; company settles 3 other cases.NEWS24: New Jersey jury finds J&J not liable in talc cancer trial; company settles three other cases.
2019-03-29: NEWS1: AstraZeneca (AZN) Signs $6.9B Cancer Deal with Daiichi Sankyo.NEWS2: AstraZeneca (AZN) Signs $6.9B Cancer Deal with Daiichi Sankyo.NEWS3: AstraZeneca (AZN) Signs $6.9B Cancer Deal with Daiichi Sankyo.NEWS4: Dow 30 Stock Roundup: Apple Launches New Services, JPMorgan to Trim Wealth Jobs.NEWS5: Dow 30 Stock Roundup: Apple Launches New Services, JPMorgan to Trim Wealth Jobs.NEWS6: Health Care Sector Update for 03/29/2019: SEEL, VTVT, AZN, JNJ, PFE, ABT, MRK, AMGN.NEWS7: Health Care Sector Update for 03/29/2019: SEEL, VTVT, AZN, JNJ, PFE, ABT, MRK, AMGN.NEWS8: Axsome's Depression Drug Gets Breakthrough Therapy Status.NEWS9: Axsome's Depression Drug Gets Breakthrough Therapy Status.
2019-04-01: NEWS1: Spero Gets Fast Track Designation for SPR994, Shares Improve.NEWS2: AstraZeneca's Selumetinib Gets Breakthrough Therapy Status.NEWS3: AstraZeneca's Selumetinib Gets Breakthrough Therapy Status.NEWS4: 5 Health Care Stocks in Gurus' Portfolios.NEWS5: Johnson & Johnson Announces Completion of Acquisition of Auris Health, Inc..NEWS6: Johnson & Johnson Completes Divestiture of Advanced Sterilization Products (ASP) to Fortive Corporation.NEWS7: Spero Gets Fast Track Designation for SPR994, Shares Improve.NEWS8: AstraZeneca's Selumetinib Gets Breakthrough Therapy Status.NEWS9: Is Johnson & Johnson the Best Stock to Hold Forever?.NEWS10: Is Johnson & Johnson the Best Stock to Hold Forever?.NEWS11: Indexes Hold Gains As These 2 Dow Stocks Top Buy Points.NEWS12: Drug companies that benefit from the war on opioid addiction.NEWS13: Airlines hit with major problem, Cable One makes acquisition, Johnson & Johnson rejects report.NEWS14: 3 Big Pharma Stocks to Add to Your Portfolio This April.NEWS15: 3 Big Pharma Stocks to Add to Your Portfolio This April.NEWS16: J&J baby shampoo samples fail Indian quality test; company rejects findings.NEWS17: Airlines hit with major problem, Cable One makes major acquisition, Johnson & Johnson rejects report.NEWS18: Is Johnson & Johnson the Best Stock to Hold Forever?.NEWS19: 3 Big Pharma Stocks to Add to Your Portfolio This April.NEWS20: Stocks making the biggest moves premarket: Kellogg, J&J, T-Mobile, PG&E & more.NEWS21: Dow set for gains | Kellogg nears deal with Ferrero | Bezos' phone data.NEWS22: Saratoga Springs communications firm growing a year after private-equity acquisition.NEWS23: Johnson & Johnson's baby shampoo samples fail Indian quality test; company rejects findings.

Answer: Decrease